Erika Lundgrin, MD
Pediatric Endocrinology · Cleveland, OHNPI 1881937654
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 39 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $541, more than ten times the $28 reported in 2019.
Across 39 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$166
- Neurocrine Biosciences, Inc.$124
- Lilly USA, LLC$99
- BETA Bionics, Inc.$89
- Corcept Therapeutics$84
- Xeris Pharmaceuticals, Inc.$83
- plus $314 from 10 others
What the payments were for
- Food & beverage$960100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 4 | $166 |
| Neurocrine Biosciences, Inc. | 5 | $124 |
| Lilly USA, LLC | 5 | $99 |
| BETA Bionics, Inc. | 3 | $89 |
| Corcept Therapeutics | 4 | $84 |
| Xeris Pharmaceuticals, Inc. | 4 | $83 |
| AstraZeneca | 3 | $79 |
| Averitas Pharma Inc. | 2 | $45 |
| Globus Medical | 2 | $44 |
| Sequel Med Tech, LLC | 1 | $29 |
| Mannkind Corporation | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
| Bavarian Nordic A/s | 1 | $20 |
| Angiodynamics, Inc. | 1 | $18 |
| Insulet Corporation | 1 | $14 |
How this compares
$960 in reported general payments places this provider in the 60th percentile of 76 pediatric endocrinology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 44 | $59,848 |
| TrulicityDulaglutide | 40 | $50,523 |
| MounjaroTirzepatide | 32 | $43,010 |
| JardianceEmpagliflozin | 16 | $28,939 |
| FarxigaDapagliflozin Propanediol | 13 | $7,170 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $5,306 |
| VascepaIcosapent Ethyl | 12 | $4,711 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $2,382 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,951 |
| Levothyroxine Sodium | 52 | $840 |
| Spironolactone | 14 | $767 |
| Hydrocortisone | 16 | $556 |
| Testosterone Cypionate | 13 | $465 |
| Chlorthalidone | 13 | $385 |
| Metformin Hcl | 12 | $239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $99 | $93,53472 claims |
| Novo NordiskOzempic | $166 | $59,84844 claims |
| AstraZenecaFarxiga | $79 | $7,17013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 76 pediatric endocrinology providers in Ohio.
Other pediatric endocrinology in Cleveland
- Sarah MacleishCleveland$19K
- Jamie WoodCleveland$8K
- Roy KimCleveland$7K
- Douglas RogersCleveland$5K
- Shashikala GowdaCleveland$2K
- Heather WadamsCleveland$820
- Ryan FarrellCleveland$739
- Ajuah DavisCleveland$584
- Naveen UliCleveland$432
- Anuradha ViswanathanCleveland$230
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.